Martin Investment Management LLC Sells 463 Shares of Stryker Co. (NYSE:SYK)

Martin Investment Management LLC trimmed its position in Stryker Co. (NYSE:SYK) by 2.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,486 shares of the medical technology company’s stock after selling 463 shares during the quarter. Stryker accounts for 1.9% of Martin Investment Management LLC’s portfolio, making the stock its 18th largest position. Martin Investment Management LLC’s holdings in Stryker were worth $7,016,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. OneAscent Financial Services LLC acquired a new stake in shares of Stryker during the 4th quarter valued at about $475,000. Huntington National Bank lifted its position in shares of Stryker by 5.9% during the 4th quarter. Huntington National Bank now owns 283,703 shares of the medical technology company’s stock worth $102,148,000 after buying an additional 15,900 shares during the period. Private Portfolio Partners LLC boosted its stake in Stryker by 14.9% in the 4th quarter. Private Portfolio Partners LLC now owns 1,120 shares of the medical technology company’s stock valued at $403,000 after buying an additional 145 shares in the last quarter. Meeder Advisory Services Inc. grew its position in Stryker by 1.5% in the fourth quarter. Meeder Advisory Services Inc. now owns 8,883 shares of the medical technology company’s stock valued at $3,198,000 after acquiring an additional 133 shares during the period. Finally, Groupama Asset Managment raised its stake in Stryker by 51.4% during the fourth quarter. Groupama Asset Managment now owns 2,007 shares of the medical technology company’s stock worth $727,000 after acquiring an additional 681 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling

In related news, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.50% of the stock is owned by insiders.

Stryker Stock Performance

Shares of SYK stock opened at $373.20 on Wednesday. The company has a fifty day moving average price of $383.41 and a two-hundred day moving average price of $374.43. The stock has a market cap of $142.45 billion, a P/E ratio of 48.09, a P/E/G ratio of 2.93 and a beta of 0.95. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a one year low of $314.93 and a one year high of $406.19.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the firm posted $3.46 earnings per share. As a group, equities analysts predict that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.90%. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on SYK. JMP Securities reissued a “market perform” rating on shares of Stryker in a report on Tuesday, February 18th. Truist Financial raised their price target on Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a report on Thursday, January 30th. Argus set a $450.00 target price on Stryker in a report on Monday, February 3rd. Citigroup reiterated a “buy” rating and set a $450.00 price target on shares of Stryker in a research report on Wednesday, February 26th. Finally, Stifel Nicolaus raised their price objective on shares of Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $421.90.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.